Learn how Veloxity Labs supported Toralgen's breakthrough oral biologics platform with advanced LC-MS/MS bioanalysis, method development and pharmacokinetic expertise.

Veloxity Labs, a leading bioanalytical CRO specializing in LC-MS bioanalysis, today announced strong first quarter growth and continued expansion in 2026.

Our CEO, Shane Needham, PhD, was recently featured in The Analytical Scientist discussing the impact of GLP-1 receptor agonists and emerging peptide therapeutics.

Veloxity Labs has acquired the SCIEX ZenoTOF 8600 system, becoming the first bioanalytical CRO to bring this accurate-mass system online. The 8600 adds HRAM selectivity/sensitivity and expanded mass range for intact peptides/proteins—speeding method cycles for GLP-1 RAs and broader peptide programs while complementing our triple-quads. Delivery is expected this year; install/qualification begins January 2026. Read the full release.

We’ve partnered with Carolina Martinez — a record-setting sprinter, Bradley University standout and cancer survivor — in a powerful new NIL collaboration.

We’re proud to support Silo Pharma in advancing SPC-15, a novel intranasal therapy for PTSD. We're providing GLP bioanalysis for their IND-enabling safety study.